Body surface distribution and response to drugs of ST segment elevation in Brugada syndrome: Clinical implication of eighty-seven-lead body surface potential mapping and its application to twelve-lead electrocardiograms

Journal of Cardiovascular Electrophysiology

Volumn 11, Issue 4, 2000, Pages 396-404

  Shimizu, Wataru ^a   Matsuo, Kiyotaka ^a   Takagi, Masahiko ^a   Tanabe, Yasuko ^a   Aiba, Takeshi ^a   Taguchi, Atsushi ^a   Suyama, Kazuhiro ^a   Kurita, Takashi ^a   Aihara, Naohiko ^a   Kamakura, Shiro ^a  

^a NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

Author keywords

Antiarrhythmic drugs; Body surface mapping; Brugada syndrome; ST segment; Ventricular fibrillation

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; DISOPYRAMIDE; ISOPRENALINE; SODIUM CHANNEL BLOCKING AGENT;

ADULT; AGED; ARTICLE; BODY SURFACE; BRUGADA SYNDROME; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ELECTROCARDIOGRAPHY; HEART RIGHT BUNDLE BRANCH BLOCK; HEART VENTRICLE FIBRILLATION; HUMAN; MALE; PRIORITY JOURNAL; ST SEGMENT ELEVATION;

EID: 0034005291     PISSN: 10453873     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1540-8167.2000.tb00334.x     Document Type: Article

References (24)

1. 1. Brugada P, Brugada J: Right bundle branch block, persistent ST segment elevation and sudden cardiac death: A distinct clinical and electrocardiographic syndrome: A multicenter report. J Am Coll Cardiol 1992;20:1391-1396.
2. 2. Brugada J, Brugada P: Further characterization of the syndrome of right bundle branch block, ST segment elevation, and sudden cardiac death. J Cardiovasc Electrophysiol 1997;8:325-331.
3. 3. A marker for sudden death in patients without demonstrable structural heart disease. Circulation 1998;97:457-460.
4. 4. Antzelevitch C: The Brugada syndrome. J Cardiovasc Electrophysiol 1998;9:513-516.
5. 5. Gussak I, Antzelevitch C, Bjerregaard P, Towbin JA, Chaitman BR: The Brugada syndrome: Clinical, electrophysiological and genetic aspects. J Am Coll Cardiol 1999;33:5-15.
6. 6. Alings M, Wilde A: Brugada syndrome: Clinical data and suggested pathophysiological mechanism. Circulation 1999;99:666-673.
7. 7. Antzelevitch C, Brugada P, Brugada J, Brugada R, Nademanee K, Towbin JA: The Brugada syndrome. In Camm AJ, ed: Clinical Approaches to Tachyarrhythmias. Futura Publishing Co., Armonk, NY, 1999, p. 1-99.
8. 8. Miyazaki T, Mitamura H, Miyoshi S, Soejima K, Aizawa Y, Ogawa S: Autonomic and antiarrhythmic drug modulation of ST segment elevation in patients with Brugada syndrome. J Am Coll Cardiol 1996;27:1061-1070.
9. 9. Atarashi H, Ogawa S, Harumi K, Hayakawa H, Sugimoto T, Okada R, Murayama M, Toyama J: Characteristics of patients with right bundle branch block and ST-segment elevation in right precordial leads. Am J Cardiol 1996;78:581-583.
10. 10. Kasanuki H, Ohnishi S, Ohtuka M, Matsuda N, Nirei T, Isogai R, Shoda M, Toyoshima Y, Hosoda S: Idiopathic ventricular fibrillation induced with vagal activity in patients without obvious heart disease. Circulation 1997;95:2277-2285.
11. 11. Nademanee K: Sudden unexplained death syndrome in southeast Asia. Am J Cardiol 1997;79(6A):10-11.
12. 12. Nademanee K, Veerakul G, Nimmannit S, Chaowakul V, Bhuripanyo K, Likittanasombat K, Tunsanga K, Kuasirikul S, Malasit P, Tansupasawadikul S, Tatsanavivat P: Arrhythmogenic marker for the sudden unexplained death syndrome in Thai men. Circulation 1997;96:2595-2600.
13. 13. Matsuo K, Shimizu W, Kurita T, Suyama K, Aihara N, Kamakura S, Shimomura K: Increased dispersion of repolarization time determined by monophasic action potentials in two patients with familial idiopathic ventricular fibrillation. J Cardiovasc Electrophysiol 1998;9:74-83.
14. 14. Matsuo K, Shimizu W, Kurita T, Inagaki M, Aihara N, Kamakura S: Dynamic changes of 12-lead electrocardiograms in a patient with Brugada syndrome. J Cardiovasc Electrophysiol 1998;9:508-512.
15. 15. Krishnan SC, Josephson ME: ST segment elevation induced by class IC antiarrhythmic agents: Underlying electrophysiologic mechanisms and insights into drug-induced proarrhythmia. J Cardiovasc Electrophysiol 1998;9:1167-1172.
16. 16. Fujiki A, Usui M, Nagasawa H, Mizumaki K, Hayashi H, Inoue H: ST segment elevation in the right precordial leads induced with class IC antiarrhythmic drugs: Insights into the mechanism of Brugada syndrome. J Cardiovasc Electrophysiol 1999;10:214-218.
17. 17. Tada H, Nogami A, Shimizu W, Nakatsugawa M, Naito S, Oshima S, Taniguchi K: ST-segment and T-wave alternans in a patient with Brugada syndrome. PACE (in press).
18. 18. Shimizu W, Kamakura S, Ohe T, Kurita T, Takaki H, Aihara N, Shimomura K: Diagnostic value of recovery time measured by body surface mapping in patients with congenital long QT syndrome. Am J Cardiol 1994;74:780-785.
19. 19. Shimizu W, Kamakura S, Kurita T, Suyama K, Aihara N, Shimomura K: Influence of epinephrine, propranolol and atrial pacing on spatial distribution of recovery time measured by body surface mapping in congenital long QT syndrome. J Cardiovasc Electrophysiol 1997;8:1102-1114.
20. 20. Watanabe T, Toyama J, Toyoshima H, Oguri H, Ohno, Ohta T, Okajima M, Naito Y, Yamada K: A practical microcomputer based mapping system for body surface, precordium, and epicardium. Comput Biomed Res 1981;14:341-354.
21. 21. Yan GX, Antzelevitch C: Cellular basis for the Brugada syndrome and other mechanisms of arrhythmogenesis associated with ST segment elevation. Circulation 1999;100:1660-1666.
22. 22. Antzelevitch C, Yan GX, Shimizu W, Burashnikov A: Electrical heterogeneity, the ECG, and cardiac arrhythmias. In Zipes DP, Jalife J, eds: Cardiac Electrophysiology: From Cell to Bedside. Third Edition. WB Saunders, Philadelphia, 1999, pp. 222-238.
23. 23. Krishnan SC, Antzelevitch C: Sodium channel blockade produces opposite electrophysiologic effects in canine ventricular epicardium and endocardium. Circ Res 1991;69:277-291.
24. 24. Krishnan SC, Antzelevitch C: Flecainide-induced arrhythmia in canine ventricular epicardium: Phase 2 reentry? Circulation 1993; 87:562-572.